Drug recall · May 8, 2019
Losartan Potassium/HCTZ recall
Why: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Losartan Potassium/HCTZ, 100 mg/12.5 mg Tablet, 90-Count bottle, Manufactured by Torrent Pharmaceuticals, Distributed by RemedyRepack, Inc. Indiana, PA, 15701-3570, NDC 70518-1560-00.
- Lots / codes
Lot #: B0517068-101618, Exp. Date: 10/2019
- Quantity
- 44 HDPE bottles of 90 = 3,960 tablets
- Company
- RemedyRepack Inc., Indiana, PA
- Distribution
- Product was distributed to Florida.
- Initiated
- April 22, 2019 · Voluntary: Firm initiated
- Classified
- May 2, 2019
- Reported
- May 8, 2019
- Ended
- May 19, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Doxazosin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.